Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.

Abstract: The present invention provides a preventive or therapeutic agent for pulmonary hypertension, including a compound represented by the following formula (I) or a salt thereof: where: —A— represents —NH—, —S—, or —O—; R1 and R2 are identical to or different from each other, and each represent a hydrogen atom or an alkyl group; R3 represents a hydrogen atom, a halogen atom, or an alkyl group; R4 represents a hydrogen atom or an alkyl group; R5 represents a hydrogen atom or an alkyl group; R6 and R7 are identical to or different each other, and each represent a hydrogen atom, a halogen atom, or an alkyl group; and R6 and R7 may form an unsaturated hydrocarbon six-membered ring together with a carbon atom to which R6 is bonded and a carbon atom to which R7 is bonded.

Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.

Abstract: The present invention provides a preventive or therapeutic agent for pulmonary hypertension, including a compound represented by the following formula (I) or a salt thereof: where: -A- represents —NH—, —S—, or —O—; R1 and R2 are identical to or different from each other, and each represent a hydrogen atom or an alkyl group; R3 represents a hydrogen atom, a halogen atom, or an alkyl group; R4 represents a hydrogen atom or an alkyl group; R5 represents a hydrogen atom or an alkyl group; R6 and R7 are identical to or different each other, and each represent a hydrogen atom, a halogen atom, or an alkyl group; and R6 and R7 may form an unsaturated hydrocarbon six-membered ring together with a carbon atom to which R6 is bonded and a carbon atom to which R7 is bonded.

Abstract: The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula: wherein R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a medicament useful for treatment and/or prevention of cancer, a vaccine adjuvant, and an inhibitor of immune checkpoint comprising a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Bonds a-d, Ring A, R1, R1?, R2, R2?, R3-R8, and n are as defined in the present specification.

Abstract: The present invention provides a medicament useful for treatment and/or prevention of cancer, a vaccine adjuvant, and an inhibitor of immune checkpoint comprising a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Bonds a-d, Ring A, R1, R1?, R2, R2?, R3-R8, and n are as defined in the present specification.

Abstract: The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula: wherein R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.

Abstract: Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.